scholarly journals Radiomics Analysis of Multi-Phase DCE-MRI in Predicting Tumor Response to Neoadjuvant Therapy in Breast Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2086
Author(s):  
Shuyi Peng ◽  
Leqing Chen ◽  
Juan Tao ◽  
Jie Liu ◽  
Wenying Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Tumor Response ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Imaging Features ◽  
Dynamic Contrast Enhancement ◽  
Post Contrast ◽  
Dce Mri ◽  
Five Phases

Objective: To explore whether the pretreatment dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) and radiomics signatures were associated with pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer. Method: A retrospective review of 70 patients with breast invasive carcinomas proved by biopsy between June 2017 and October 2020 (26 patients were pathological complete response, and 44 patients were non-pathological complete response). Within the pre-contrast and five post-contrast dynamic series, a total of 1037 quantitative imaging features were extracted from in each phase. Additionally, the Δfeatures (the difference between the features before and after the comparison) were used for subsequent analysis. The least absolute shrinkage and selection operator (LASSO) regression method was used to select features related to pCR, and then use these features to train multiple machine learning classifiers to predict the probability of pCR for a given patient. The area under the curve (AUC), accuracy, sensitivity, and specificity were calculated to assess the predictive performances of the radiomics model for each of the five phases of time points. Result: Among the five phases, each individual phase performed with AUCs ranging from 0.845 to 0.919 in predicting pCR. The best single phases performance was given by the 3rd phase (AUC = 0.919, sensitivity 0.885, specificity 0.864). 5 of the features have significant differences between pCR and non-pCR groups in each phase, most features reach their maximum or minimum in the 2nd or 3rd phase. Conclusion: The radiomic features extracted from each phase of pre-treatment DCE-MRI possess discriminatory power to predict tumor response.

Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 583-583
Author(s):  
Christine Brunner ◽  
Thomas Jaeger ◽  
Christoph Suppan ◽  
Elisabeth Mueller-Holzner ◽  
Zerina Jasarevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Liposomal Doxorubicin ◽  
Pathological Complete Response ◽  
Neoadjuvant Treatment ◽  
Complete Response ◽  
Left Ventricular Ejection ◽  
Cardiac Safety ◽  
Multicenter Analysis

583 Background: Concurrent therapy of trastuzumab, anthracycline and taxane for the neoadjuvant treatment of breast cancer (BC) results in an improved rate of pathological complete response (pCR). However, there is considerable concern about the cardiac safety of this combination. The use of liposomal doxorubicin might be a valuable alternative with lower cardiotoxicity. We report cardiac safety and pCR-rate of a single arm, retrospective, multicenter analysis of neoadjuvant treatment for BC with liposomal doxorubicin, trastuzumab, and docetaxel. Methods: In this study 84 women with BC and HER2 overexpression were investigated in 3 oncological departments in Austria. All patients were treated with liposomal doxorubicin (50 - 60 mg/m²), docetaxel (75 mg/m²) and concurrent with trastuzumab for 6 cycles as neoadjuvant therapy. All patients were free of cardiovascular disease and had a left ventricular ejection fraction (LVEF) of ≥ 55%. Cardiac function was by LVEF and was examined at regular intervals(cycles 0-3, cycle 6, FU). Clinical response was evaluated by diagnostic breast imaging after cycles 3 and 6. All patients underwent surgery after neoadjuvant chemotherapy. The absence of any residual invasive cancer in the breast and axilla was defined as pathological complete response (pCR). Median follow up was 2.4 years. Results: Median age of the patients was 50 years. After 6 cycles of treatment the pCR rate was 46%. In this cohort a negative estrogen-and/or progesteron receptor was predictive for pCR (p<0.001). No patient progressed during treatment. None of the patients suffered symptomatic heart failure. Only one patient (1.6%) with asymptomatic LVEF of 45% was observed during follow-up. Conclusions: In this multicenter analysis we observed a considerably high rate of pCR in HER2-positive BC treated with liposomal doxorubicin, docetaxel and trastuzumab. The addition of liposomal doxorubicin instead of conventional doxorubicin or epirubicin entails a very favorable cardiotoxicity profile. This regimen is a safe treatment option in patients with HER-2 positive breast cancer.

scholarly journals A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer

Tumor Biology ◽  
2017 ◽  
Vol 39 (6) ◽  
pp. 101042831770289 ◽  
Author(s):  
Raúl García-Vazquez ◽  
Erika Ruiz-García ◽  
Abelardo Meneses García ◽  
Horacio Astudillo-de la Vega ◽  
Fernando Lara-Medina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Therapy Regimen

Neoadjuvant Study of Niraparib in Patients With HER2-Negative, BRCA-Mutated Resectable Breast Cancer

2021 ◽  
Author(s):  
Laura Spring ◽  
Hyo Han ◽  
Minetta Liu ◽  
Erika Hamilton ◽  
Hanna Irie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Antitumor Activity ◽  
Tumor Response ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Once Daily ◽  
Safety Signals

Abstract This study evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6/15) of patients who only received niraparib (2–6 cycles) had pathological complete response. No new safety signals were identified and high niraparib intratumoral concentration was observed.

Sign in / Sign up

Export Citation Format

Share Document